Vor is a biotech company advancing telitacicept, a first-in-class dual BAFF/APRIL inhibitor, to address autoimmune disease at its root.
Join Vor in tackling autoimmune disease at its root by advancing telitacicept, a first-in-class dual BAFF/APRIL inhibitor. The Associate Director of Advocacy will support and execute Vor's patient engagement strategy, engaging with patient communities, advocacy organizations, and stakeholders.
Vor is a biotech company advancing telitacicept, a first-in-class dual BAFF/APRIL inhibitor, to address autoimmune disease at its root.
Vor Bio